Eli Lilly and Company $LLY Stake Increased by Simplify Asset Management Inc.

Simplify Asset Management Inc. raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 104.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,088 shares of the company’s stock after buying an additional 15,373 shares during the quarter. Eli Lilly and Company comprises approximately 0.6% of Simplify Asset Management Inc.’s holdings, making the stock its 9th largest position. Simplify Asset Management Inc.’s holdings in Eli Lilly and Company were worth $34,814,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in LLY. Financial Insights Inc. raised its stake in Eli Lilly and Company by 3.5% during the third quarter. Financial Insights Inc. now owns 846 shares of the company’s stock valued at $979,000 after purchasing an additional 29 shares in the last quarter. Prism Planning Partners LLC purchased a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $184,000. BLB&B Advisors LLC boosted its holdings in Eli Lilly and Company by 8.6% during the 3rd quarter. BLB&B Advisors LLC now owns 11,585 shares of the company’s stock valued at $13,405,000 after acquiring an additional 915 shares during the period. AMI Investment Management Inc. lifted its position in shares of Eli Lilly and Company by 55.2% during the third quarter. AMI Investment Management Inc. now owns 405 shares of the company’s stock worth $469,000 after purchasing an additional 144 shares during the last quarter. Finally, Sigma Investment Counselors Inc. boosted its stake in shares of Eli Lilly and Company by 3.2% during the third quarter. Sigma Investment Counselors Inc. now owns 1,357 shares of the company’s stock valued at $1,570,000 after purchasing an additional 42 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on LLY shares. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research note on Friday. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday. Scotiabank raised their price objective on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a research report on Friday. Leerink Partners increased their price target on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a research note on Wednesday, October 21st. Finally, Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,398.43.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 over the last ninety days. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY opened at $1,415.64 on Friday. The firm has a fifty day moving average price of $1,197.72 and a 200 day moving average price of $1,092.57. The stock has a market cap of $1.33 trillion, a P/E ratio of 45.95, a P/E/G ratio of 1.73 and a beta of 0.46. Eli Lilly and Company has a 1 year low of $834.19 and a 1 year high of $1,449.68. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 93.68% and a net margin of 31.90%. The company’s quarterly revenue was up 38.6% on a year-over-year basis. During the same period last year, the firm earned $7.02 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 35.50 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is presently 23.22%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.